{"id":7004,"date":"2026-02-20T11:24:38","date_gmt":"2026-02-20T05:54:38","guid":{"rendered":"https:\/\/mdforlives.blog\/?p=7004"},"modified":"2026-05-19T17:59:54","modified_gmt":"2026-05-19T12:29:54","slug":"erenumab","status":"publish","type":"post","link":"https:\/\/mdforlives.com\/blog\/erenumab\/","title":{"rendered":"Erenumab: What It Is, Uses, Administration & How It Works"},"content":{"rendered":"

Erenumab is one of the most widely recognized CGRP-targeting therapies used for migraine prevention in adults. Approved under the brand name Aimovig, the medication represents an important shift in preventive migraine treatment, particularly for patients who do not respond adequately to traditional therapies.<\/span>\u00a0<\/span><\/p>\n

Unlike older migraine medications originally developed for epilepsy, hypertension, or depression, erenumab was specifically designed to target migraine-related biological pathways. The therapy works by blocking the calcitonin gene-related peptide (CGRP) receptor, which plays a central role in migraine pathophysiology and pain signaling.<\/span>\u00a0<\/span><\/p>\n

As migraine management increasingly moves toward targeted neurological care, biologic therapies such as erenumab are becoming more important within preventive treatment strategies. Neurologists and headache specialists are also paying closer attention to long-term efficacy, patient quality of life, treatment adherence, and safety outcomes associated with CGRP inhibitor therapies.<\/span>\u00a0<\/span><\/p>\n

Erenumab reflects a broader transition in migraine care from generalized symptom management toward targeted biologic intervention focused on migraine-specific mechanisms.<\/span><\/b>\u00a0<\/span><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n